EPO

EPO Full Name

erythropoietin

EPO Introduction

Erythropoietin (EPO) is a glycoprotein hormone that plays a central role in regulating red blood cell production and maintaining oxygen homeostasis in the human body. Primarily produced by peritubular interstitial cells in the kidney, EPO is released in response to reduced oxygen availability and acts by binding to the Erythropoietin receptor on erythroid progenitor cells in the bone marrow. This interaction activates intracellular signaling pathways that promote cell survival, proliferation, and differentiation into mature erythrocytes. Because oxygen delivery is essential for tissue metabolism, the EPO–EPOR signaling axis has become a critical biological target in hematology, sports medicine, and therapeutic protein development. Researchers and clinicians frequently encounter challenges when interpreting abnormal erythropoietin levels, especially when distinguishing between physiological responses to hypoxia and pathological or pharmacological influences.

Beyond its classical role in erythropoiesis, EPO has emerged as a multifunctional cytokine involved in diverse physiological processes. Transcriptomic and systems-biology analyses of recombinant human EPO stimulation have revealed extensive gene expression changes affecting oxygen transport, immune regulation, and cellular stress responses. These findings indicate that EPO signaling participates in broader biological networks rather than acting solely as a hematopoietic hormone. In addition, the structure of EPO is heavily influenced by complex glycosylation patterns, which determine its stability, receptor affinity, and In Vivo half-life. Advances in chemical synthesis and glycoengineering have enabled the production of homogeneous EPO glycoforms, allowing researchers to study structure–function relationships in greater detail and supporting the development of improved EPO-based therapeutics with optimized pharmacokinetic profiles.

Dysregulation of EPO expression or signaling is associated with several hematologic and genetic disorders, making it an important diagnostic and therapeutic biomarker. Reduced EPO production is a major contributor to anemia in chronic kidney disease, while excessive or ectopic EPO expression can lead to erythrocytosis. Recent genetic studies have identified novel mutations in the EPO gene that alter transcriptional regulation or protein structure. For example, promoter mutations can create new hypoxia-responsive regulatory elements that drive abnormal EPO expression outside the kidney, leading to inherited erythrocytosis. Other variants may modify the biochemical properties of circulating EPO, complicating clinical interpretation and anti-doping testing. As a result, precise analytical strategies—such as advanced glycoform analysis and sensitive immunodetection methods—are increasingly important for distinguishing endogenous EPO variants from therapeutic recombinant erythropoietin and for improving diagnostic accuracy in both clinical and regulatory settings.

Alternate Names for EPO

EPO; erythropoietin; EP; MVCD2; epoetin;

• 1.Lanikova L, et al.; Autosomal Dominant Erythrocytosis Caused by Non-Renal Erythropoietin (EPO) Due to EPO c.-136 G>A Germline Mutation. Am J Hematol. 2026 Jan 23.
  2.Wang Y, et al.; Recent Progress in the Synthesis of Homogeneous Erythropoietin (EPO) Glycoforms. Chembiochem. 2020, 21(23):3301-3312.